Deals in Depth: June/July 2009
Executive Summary
J&J made news in July by forming a JV with Elan that will develop the latter's Alzheimer's program--including the highly touted Phase III candidate bapineuzumab--in a deal valued at $1.5bn; BMS acquired antibody technologies in its $2bn takeover of Medarex; and financing for medical device firms grew in June and July with most of the money coming from late-stage venture rounds, while biopharma fundraising went down in June but rebounded the following month thanks to a strong showing from follow-on public offerings.
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports